JP2021525076A5 - - Google Patents
Info
- Publication number
- JP2021525076A5 JP2021525076A5 JP2020565312A JP2020565312A JP2021525076A5 JP 2021525076 A5 JP2021525076 A5 JP 2021525076A5 JP 2020565312 A JP2020565312 A JP 2020565312A JP 2020565312 A JP2020565312 A JP 2020565312A JP 2021525076 A5 JP2021525076 A5 JP 2021525076A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antigen
- nucleic acid
- mhc class
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024153547A JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675649P | 2018-05-23 | 2018-05-23 | |
| US201862675559P | 2018-05-23 | 2018-05-23 | |
| US62/675,649 | 2018-05-23 | ||
| US62/675,559 | 2018-05-23 | ||
| PCT/US2019/033830 WO2019226941A1 (en) | 2018-05-23 | 2019-05-23 | Shared antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153547A Division JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525076A JP2021525076A (ja) | 2021-09-24 |
| JP2021525076A5 true JP2021525076A5 (enExample) | 2022-05-27 |
| JP7554119B2 JP7554119B2 (ja) | 2024-09-19 |
Family
ID=68617213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565312A Active JP7554119B2 (ja) | 2018-05-23 | 2019-05-23 | 共有抗原 |
| JP2024153547A Pending JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153547A Pending JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210196806A1 (enExample) |
| EP (1) | EP3796927A4 (enExample) |
| JP (2) | JP7554119B2 (enExample) |
| KR (1) | KR20210013105A (enExample) |
| CN (1) | CN112368386A (enExample) |
| AU (2) | AU2019275072A1 (enExample) |
| CA (1) | CA3099644A1 (enExample) |
| IL (1) | IL278864B1 (enExample) |
| TW (1) | TW202000907A (enExample) |
| WO (1) | WO2019226941A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| MA49156A (fr) | 2014-12-23 | 2020-03-25 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| LT3388075T (lt) | 2015-03-27 | 2023-11-10 | Immatics Biotechnologies Gmbh | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003) |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| WO2020037302A1 (en) * | 2018-08-17 | 2020-02-20 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020186064A1 (en) * | 2019-03-12 | 2020-09-17 | The General Hospital Corporation | Highly networked immunogen composition |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| KR20220098379A (ko) * | 2019-11-15 | 2022-07-12 | 그릿스톤 바이오, 인코포레이티드 | 공유 네오항원을 표적으로 하는 항원-결합 단백질 |
| JP2023522512A (ja) * | 2019-11-18 | 2023-05-31 | エピヴァックス セラピューティクス インコーポレイテッド | 共通のネオエピトープワクチンのための改善された組成物及び方法 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| WO2021119545A1 (en) * | 2019-12-11 | 2021-06-17 | Gritstone Bio, Inc. | Durable vaccination |
| EP4138890A4 (en) * | 2020-04-21 | 2024-07-31 | Gritstone bio, Inc. | ANTIGEN CODING CASSETTES |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| JP2023541671A (ja) * | 2020-09-17 | 2023-10-03 | プロシーナ バイオサイエンシーズ リミテッド | シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| EP4255477A4 (en) * | 2020-12-03 | 2024-11-06 | Gritstone bio, Inc. | HOMOLOGATED ADENOVIRAL VACCINATION |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| CN116867799A (zh) * | 2021-02-10 | 2023-10-10 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
| AU2022256469A1 (en) * | 2021-04-14 | 2023-10-12 | Academisch Ziekenhuis Leiden | Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2022229966A1 (en) | 2021-04-29 | 2022-11-03 | Yeda Research And Development Co. Ltd. | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same |
| TWI804229B (zh) * | 2021-09-27 | 2023-06-01 | 美商圖策智能科技有限公司 | 基於蛋白質突變預測的蛋白質結合自由能估測方法及系統 |
| CN115785206B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标07及其用途 |
| CN115785208B (zh) * | 2022-06-10 | 2024-07-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标01及其用途 |
| CN115785204B (zh) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标08及其用途 |
| CN115785205B (zh) * | 2022-06-10 | 2024-08-30 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标09及其用途 |
| CN115785209B (zh) * | 2022-06-10 | 2024-08-02 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标06及其用途 |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| CN115785207B (zh) * | 2022-06-10 | 2024-08-30 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标02及其用途 |
| CN115785211B (zh) * | 2022-06-10 | 2024-09-24 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标04及其用途 |
| WO2024136608A1 (ko) * | 2022-12-23 | 2024-06-27 | 한미약품 주식회사 | 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도 |
| CN116183907B (zh) * | 2023-03-09 | 2025-03-25 | 巴迪泰（广西）生物科技有限公司 | 一种基于抗原捕捉磁珠技术的抗原富集与清洗方法及系统 |
| WO2024216073A1 (en) * | 2023-04-14 | 2024-10-17 | The Trustees Of Columbia University In The City Of New York | Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy |
| WO2024254461A2 (en) * | 2023-06-07 | 2024-12-12 | Nutech Ventures | Methods and compositions for vaccine development and delivery |
| GB202400424D0 (en) * | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| CN121464216A (zh) * | 2024-01-17 | 2026-02-03 | 艾博生物科技(上海)有限公司 | 用于诱导针对kras突变细胞的抗原特异性免疫的组合物和方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| ES2180045T3 (es) * | 1996-04-19 | 2003-02-01 | Us Gov Sec Health | Peptidos ras mutados para la generacion de linfocitos t citotoxicos cd8+. |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| US20040248113A1 (en) * | 1999-12-28 | 2004-12-09 | Alessandro Sette | Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
| WO2001055393A2 (en) * | 2000-01-28 | 2001-08-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| CA2500955A1 (en) | 2002-10-03 | 2004-04-15 | Genencor International, Inc. | Optimized multi-epitope constructs and uses thereof |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| CN101579528B (zh) * | 2009-06-24 | 2011-06-29 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种hiv复合多表位dna疫苗及其应用 |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| KR102759126B1 (ko) | 2010-12-30 | 2025-01-24 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| TWI636065B (zh) * | 2013-08-05 | 2018-09-21 | 伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| IL294183B2 (en) * | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| ES2970865T3 (es) * | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| SG11201811442UA (en) * | 2016-06-20 | 2019-01-30 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
| JP2020500552A (ja) * | 2016-11-23 | 2020-01-16 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のウイルスによる送達方法 |
| GB201621732D0 (en) * | 2016-12-20 | 2017-02-01 | Agricultural Research Council | A multi-epitope dna vaccine for heartwater |
| CA3060569A1 (en) | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| AU2018279627B2 (en) * | 2017-06-09 | 2023-08-10 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
-
2019
- 2019-05-23 AU AU2019275072A patent/AU2019275072A1/en not_active Abandoned
- 2019-05-23 JP JP2020565312A patent/JP7554119B2/ja active Active
- 2019-05-23 IL IL278864A patent/IL278864B1/en unknown
- 2019-05-23 CA CA3099644A patent/CA3099644A1/en active Pending
- 2019-05-23 KR KR1020207036368A patent/KR20210013105A/ko active Pending
- 2019-05-23 WO PCT/US2019/033830 patent/WO2019226941A1/en not_active Ceased
- 2019-05-23 TW TW108117933A patent/TW202000907A/zh unknown
- 2019-05-23 CN CN201980034786.XA patent/CN112368386A/zh active Pending
- 2019-05-23 EP EP19808088.9A patent/EP3796927A4/en active Pending
- 2019-05-23 US US17/058,128 patent/US20210196806A1/en active Pending
-
2024
- 2024-09-06 JP JP2024153547A patent/JP2024178211A/ja active Pending
-
2026
- 2026-01-16 AU AU2026200326A patent/AU2026200326A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525076A5 (enExample) | ||
| JP2023526495A5 (enExample) | ||
| JP2022512912A5 (enExample) | ||
| JP2023541108A5 (enExample) | ||
| JP2022539417A5 (enExample) | ||
| JP2021524247A5 (enExample) | ||
| EP3177720B1 (en) | Virus like particle comprising modified envelope protein e3 | |
| US20230270841A1 (en) | Coronavirus vaccine | |
| JP2023523414A5 (enExample) | ||
| JP2022534282A5 (enExample) | ||
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2021525076A (ja) | 共有抗原 | |
| JP2021524247A (ja) | 免疫チェックポイント阻害剤の共発現ベクター | |
| EP3423473A2 (en) | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity | |
| JP2022512912A (ja) | アルファウイルス新生抗原ベクター及びインターフェロン阻害因子 | |
| JP2023523413A5 (enExample) | ||
| JP2023521662A5 (enExample) | ||
| Lundstrom | Alphavirus vectors for vaccine production and gene therapy | |
| CN111630060A (zh) | 用于在疾病的预防和/或治疗中使用的疫苗 | |
| BR112015023524B1 (pt) | Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune | |
| CN116096409A (zh) | 编码稳定化的冠状病毒刺突蛋白的rna复制子 | |
| JP2004501646A5 (enExample) | ||
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| JP2024510610A (ja) | 人工アルファウイルス由来ｒｎａレプリコン発現系 | |
| JP2020532287A (ja) | 癌の治療のためのネオアンチゲンワクチン組成物 |